US2006074106A1PendingUtilityA1
Treatment of inflammatory disorders
Individually held — no corporate assignee on recordPriority: Sep 5, 2000Filed: Nov 30, 2005Published: Apr 6, 2006
Est. expirySep 5, 2020(expired)· nominal 20-yr term from priority
A61P 31/04A61P 37/00A61P 29/00A61P 11/08A61P 19/00A61P 1/04A61P 19/02A61P 11/06A61P 1/00A61K 31/49A61P 17/06
46
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of treating an inflammatory disease or an autoimmune disease in a subject, comprises the administration of mefloquine.
Claims
exact text as granted — not AI-modified1 . Use of (+)-erythro-mefloquine, substantially free of (−)-erythro-mefloquine, for the manufacture of a medicament for the treatment of an inflammatory disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, ulcerative colitis, COPD and asthma.
2 . The use, according to claim 1 , wherein the inflammatory disease is rheumatoid arthritis.
3 . The use, according to claim 1 , wherein the inflammatory disease is osteoarthritis.
4 . A method for treating an inflammatory disease selected from the group consisting of rheumatoid arthritis, osteoarthritis, psoriatic arthritis, psoriasis, Crohn's disease, systemic lupus erythematosus, ulcerative colitis, COPD and asthma, wherein said method comprises administering, to a patient in need of such treatment, (+)-erythro-mefloquine, substantially free of (−)-erythro-mefloquine.
5 . The method, according to claim 4 , wherein the inflammatory disease is rheumatoid arthritis.
6 . The method, according to claim 4 , wherein the inflammatory disease is osteoarthritis.
7 . The method, according to claim 4 , further comprising first identifying said patient in need.Join the waitlist — get patent alerts
Track US2006074106A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.